MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.270
+0.010 (0.79%)
Apr 24, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Earnings Call Transcripts
Fiscal Year 2025
-
THIO, a novel telomere-targeting immunotherapy, is advancing through pivotal trials for hard-to-treat cancers, showing high efficacy and safety. Multiple partnerships, orphan drug designations, and a strong patent portfolio support its commercial potential, with key data and regulatory milestones expected through 2026.